Yan Wang

Dr. Yan Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
XJXiaoli Ji
Xiaoli Ji
QHQuan Hu
Quan Hu
CYChengcheng Yang
Chengcheng Yang
LHLi Huang
Li Huang
YHYefang Huang
Yefang Huang
YWYan Wang
Yan Wang
Objective: The sequelae of pelvic inflammatory disease (SPID) are major causes of secondary infertility. Modified Hongteng Baijiang decoction (MHTBD) has produced positive results in the treatment of patients with chronic pelvic inflammatory disease; however, its role in SPID remains elusive. Therefore, this study clarified the role of MHTBD in SPID pathogenesis.Methods: The main components in MHTBD were analyzed by using liquid chromatography‒mass spectrometry (LC/MS). An SPID rat model was established, and the rats were treated with different doses of MHTBD (0.504 g of raw drug/kg, 1.008 g of raw drug/kg, and 2.016 g of raw drug/kg). Endometrial pinopodes were observed via scanning electron microscopy, endometrial thickness and inflammatory cell infiltration were assessed via HE staining, and the expression of estrogen receptor (ER), progesterone receptor (PR), integrin β3 (ITGB3), and CD31 in the endometrium was detected by using immunohistochemistry. Western blot analysis was used to detect the protein expression of LIF, JAK2, p‐JAK2, STAT3, and p‐STAT3 in the endometrium. Moreover, the changes in the gut microbiota were analyzed via 16S rRNA sequencing.Results: MHTBD improved endometrial receptivity, attenuated endometrial pathologic damage, reduced inflammatory cell infiltration, decreased ER and PR expression in the endometrium, and promoted the expression of LIF, p‐JAK2, and p‐STAT3 in the endometrium (p < .05) in SPID rats. Additionally, MHTBD treatment affected the composition of the gut microbiota in SPID rats. Furthermore, MHTBD attenuated endometrial receptivity and pathological damage in SPID rats by promoting the LIF/JAK2/STAT3 pathway.Conclusion: MHTBD attenuates SPID in rats by promoting the LIF/JAK2/STAT3 pathway and improving the composition of the gut microbiota. MHTBD may be a valuable drug for SPID therapy.

1 August 2025 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
JLJunjie Li
Junjie Li
LYLeilei Yang
Leilei Yang
YWYan Wang
Yan Wang
MHMin He
Min He
HZHongqiu Zhu
Hongqiu Zhu
YHYefang Huang
Yefang Huang
Hysteroscopic myomectomy is the first-line treatment for the removal of submucosal myoma in women facing fertility requirements. However, in the face of large diameter type 2 submucosal myoma, patients are at greater risk of complications such as uterine perforation and fluid overload during hysteroscopy. When the diameter of type 2 submucous myoma is greater than 4cm, the three-phase treatment of high intensity focused ultrasound (HIFU), drugs and hysteroscopy is effective and safe. We shared a case of a 30-year-old non-pregnant woman, who had a history of uterine submucous myoma for more than 4 years with symptoms of heavy menstruation, prolonged menstruation and secondary severe anemia. The patient’s initial pelvic magnetic resonance results suggested a type 2 uterine submucous myoma with a diameter of more than 4cm. We first performed HIFU on the patient, followed by the patient’s oral intake of mifepristone tablets for 3 months, and prior to hysteroscopic surgery, the patient’s fibroid type was shifted to type 0, and finally successfully completed hysteroscopic myomectomy (HM). Finally, we conclude that when the diameter of type 2 submucosal myoma exceeds 4 cm, preoperative application of HIFU combined with drug treatment should be considered to maximize the reduction of fibroids, improve symptoms such as anemia and dysmenorrhea, reduce the time required for hysteroscopic surgery, and improve the safety of surgery.

23 April 2024 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
XJXiaoli Ji
Xiaoli Ji
QHQuan Hu
Quan Hu
CYChengcheng Yang
Chengcheng Yang
LHLi Huang
Li Huang
YHYefang Huang
Yefang Huang
YWYan Wang
Yan Wang

26 November 2025 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
LHLi Huang
Li Huang
XYXiaolan Yin
Xiaolan Yin
YWYan Wang
Yan Wang
SWShaobin Wei
Shaobin Wei
XJXiaoli Ji
Xiaoli Ji
CYChengcheng Yang
Chengcheng Yang

30 April 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
YMYuyang Mi
Yuyang Mi
YWYan Wang
Yan Wang
QLQian Liu
Qian Liu
LHLi Huang
Li Huang
MLMaoya Li
Maoya Li
MLMin Liu
Min Liu
Objective: To systematically evaluate the efficacy of Traditional Chinese Medicine (TCM) as an adjunctive modality in postoperative ovarian cancer management, specifically focusing on its capacity for toxicity reduction and immune reconstitution. Methods: Literature was systematically searched across six databases (China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, SinoMed, PubMed, and the Cochrane Library.) for literature published between January 2018 and June 2025. Randomized controlled trials (RCTs) were included if they compared integrative therapy (TCM plus conventional platinum-based chemotherapy) to conventional therapy alone in postoperative patients with ovarian cancer. The primary endpoint was the incidence of chemotherapy-related adverse events (AEs), while secondary endpoints included immune cell subsets (CD3 + , CD4 + , CD4 + /CD8 + ratio), and Karnofsky Performance Status (KPS). Data were synthesized using random- or fixed-effect models based on heterogeneity ( I 2 ). Results: Twenty-two RCTs ( n = 1719) met inclusion criteria. Adjunctive TCM significantly reduced chemotherapy-related AEs (RR = 0.35, 95% CI 0.27–0.46; I 2 =0%), and increased T-cell subsets: CD3 + levels improved (MD = 11.74, 95% CI 10.62–12.85; I 2 =0%) and CD4 + levels increased (MD = 10.04, 95% CI 7.31–12.78; I 2 =93%), whereas the CD4 + /CD8 + ratio did not show a statistically significant difference (SMD = 3.22, 95% CI 2.41–4.04; I 2 =90%). KPS scores were higher in the TCM group (MD = 13.06, 95% CI 11.97–14.15; I 2 =93%). Conclusion: The integration of TCM with postoperative chemotherapy provided dual benefit of reducing treatment toxicity and enhancing cellular immune recovery in patients with ovarian cancer. Due to limitations in study quality and heterogeneity, further high-quality RCTs are needed to validate these findings and establish standardized TCM protocols. Systematci review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251242407 , CRD420251242407.

5 September 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YWYan Wang
Yan Wang
YHYefang Huang
Yefang Huang
LSLing Shi
Ling Shi
LHLi Huang
Li Huang
YWYi Wen
Yi Wen
XJXiaoli Ji
Xiaoli Ji
Sequela of pelvic inflammatory disease (SPID) is a common and frequently occurring disease clinically. Traditional Chinese medicine (TCM) provided unique advantages in the treatment of SPID. In this study, we aimed to investigate the protective mechanism of Shipi Shugan Decoction (SSD), a Chinese herbal formula, on SPID using a SPID rat model. Mixed bacterial infection and mechanical injury were used for modeling. The chemical composition of SSD was analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). The inflammatory factors were detected by enzyme-linked immunosorbent assay (ELISA) and western blot techniques. We found that SSD dose-dependently inhibited the content of IL-18, IL-1β, TNF-α, and IL-6 in serum samples of SPID rats. The results from the hematoxylin and eosin (H&E) stain showed that SSD improved pathological injury of the uterus and fallopian tubes induced by a pathogen. In addition, SSD dose-dependently inhibited mitochondrial dysfunction and oxidative stress of SPID rats. The expression of SIRT1 was promoted, and NLRP3 inflammasome was deactivated by SSD gavage compared with the SPID group. Specifically, SIRT1 inhibitor EX-527 cotreatment significantly reversed the improvement effect of SSD on pelvic inflammatory disease in rats. Taken together, the results of this study suggest that Shipi Shugan Decoction may be an effective TCM for the treatment of SPID.